2022
The Independent Effect of Exercise on Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review
Chen G, Banini B, Do A, Lim J. The Independent Effect of Exercise on Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review. Clinical And Molecular Hepatology 2022, 29: s319-s332. PMID: 36517000, PMCID: PMC10029942, DOI: 10.3350/cmh.2022.0366.Peer-Reviewed Original ResearchConceptsNon-alcoholic fatty liver diseaseBiopsy-proven non-alcoholic fatty liver diseaseNon-invasive testsFatty liver diseaseHepatic steatosisLiver fibrosisLiver diseaseHistological endpointsIndependent effectsSystematic reviewNon-randomized interventional studyMagnetic resonance imaging-based techniquesAdditional large RCTsChronic liver diseaseSignificant histological improvementEffects of exerciseClinical outcome endpointsSystematic literature searchHistological improvementExercise interventionHepatocyte ballooningOriginal research studiesLarge RCTsOutcome endpointsInterventional study
2020
Knockout of sulfatase 2 is associated with decreased steatohepatitis and fibrosis in a mouse model of nonalcoholic fatty liver disease
Kim TH, Banini BA, Asumda FZ, Campbell NA, Hu C, Moser CD, Shire AM, Han S, Ma C, Krishnan A, Mounajjed T, White TA, Gores GJ, LeBrasseur NK, Charlton MR, Roberts LR. Knockout of sulfatase 2 is associated with decreased steatohepatitis and fibrosis in a mouse model of nonalcoholic fatty liver disease. AJP Gastrointestinal And Liver Physiology 2020, 319: g333-g344. PMID: 32683952, PMCID: PMC7509257, DOI: 10.1152/ajpgi.00150.2019.Peer-Reviewed Original ResearchConceptsFast food dietStandard chow dietWT miceDiet-induced steatohepatitisNonalcoholic steatohepatitisSulfatase 2Hepatic fibrosisMouse modelStandard chow diet ad libitumChow diet ad libitumNonalcoholic fatty liver diseaseDiet-induced mouse modelConditions of overnutritionProtein expressionFatty liver diseasePotential therapeutic mechanismWild-type miceDiet ad libitumThreefold increaseLiver diseaseChow dietKO miceLiver fibrosisSteatohepatitisMurine model
2019
Vitamin E in Nonalcoholic Fatty Liver Disease
Banini B, Sanyal A. Vitamin E in Nonalcoholic Fatty Liver Disease. Nutrition And Health 2019, 311-323. DOI: 10.1007/978-3-030-05315-4_23.ChaptersNonalcoholic fatty liver diseaseVitamin E supplementationChronic liver diseaseFatty liver diseaseNonalcoholic steatohepatitisLiver diseaseE supplementationVitamin ESubtype of NAFLDAnnual direct medical costsChronic viral hepatitisAlcoholic liver diseaseClinical practice guidelinesDirect medical costsLong-term useNAFLD patientsLabel treatmentViral hepatitisPharmacological therapyComplex pathogenesisHistological featuresLiver fibrosisClinical trialsLeading causeClinical studies
2014
Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling
Nakamura I, Zakharia K, Banini BA, Mikhail DS, Kim TH, Yang JD, Moser CD, Shaleh HM, Thornburgh SR, Walters I, Roberts LR. Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling. PLOS ONE 2014, 9: e92273. PMID: 24710173, PMCID: PMC3977817, DOI: 10.1371/journal.pone.0092273.Peer-Reviewed Original ResearchMeSH KeywordsAlanineAnimalsCarbon Tetrachloride PoisoningCell LineCell ProliferationCell SurvivalCollagen Type ICollagen Type I, alpha 1 ChainFibroblast Growth FactorsHepatic Stellate CellsHumansImmunohistochemistryLiver CirrhosisLiver NeoplasmsMicePlatelet-Derived Growth FactorProtein Kinase InhibitorsSignal TransductionTriazinesVascular Endothelial Growth Factor AConceptsVascular endothelial growth factor receptorHuman hepatic stellate cellsBile duct ligationLiver fibrosisStellate cell activationPlatelet-derived growth factorCell activationHuman hepatic stellate cell activationChronic thioacetamide administrationHepatic stellate cell activationInhibition of VEGFREndothelial growth factor receptorChronic carbon tetrachlorideNovel therapeutic approachesHepatic stellate cellsStellate cell proliferationSmooth muscle actinDifferent animal modelsLX-2 human hepatic stellate cellsGrowth factor receptorHepatic fibrosisBrivanibDuct ligationLiver cancerTherapeutic approaches